News
Lasting benefit with nivo plus ipi in advanced HCC
The duration of response approached 4 years in some patients.
News
TACTICS: TACE plus sorafenib improves PFS in unresectable HCC
Adding chemoembolization to sorafenib did not improve overall survival, but the results may have been skewed by differences in post-TACE therapies...
News
The jury’s still out on trifluridine/tipiracil plus bevacizumab in mCRC
Phase 3 results may provide more insight.
News
Triplet shows ‘promising’ activity in unresectable/metastatic CRC
Panitumumab plus ipilimumab and nivolumab induced responses in more than a third of patients.
Article
Coronasomnia: Pervasive sleeplessness, self-medicating raise concerns of sleep experts
Lockdown-related stress and psychological factors may play a role, but SARS-CoV-2 may also have still-unrecognized central nervous system effects...